Pembrolizumab in first-line monotherapy compared to platinum compound-based chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with locally advanced or advanced NSCLC with PD-L1 expression on at least 1% of tumor cells [5]. The gene discussed is CD274; the disease is neoplasm.